Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter study of envafolimab monotherapy in dMMR/MSI-H advanced colorectal cancer and other advanced solid tumors
CTR20181127Phase 2Active
- Sponsor
- Alphamab Oncology
- Start
- Aug 2018
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in colorectal cancer (CRC), Nonhematologic neoplasms, sponsored by Alphamab Oncology. Started Aug 2018; status: active.
02
Drugs
envafolimab
03
Conditions
colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20181127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181127.